Predicting Individual Prognosis and Treatment Response in Advanced Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer and the sixth leading cause of cancer death in males worldwide. Over 250,000 new prostate cancer cases diagnosed in the U.S. in 2013, with 28,000 deaths. When selecting treatment regimens for advanced prostate cancer, physicians typically rely on the patient's prostate-specific antigen (PSA) level as the primary surrogate biomarker. However, this biomarker (or any single biomarker) is not enough to indicate an individual patient's prognosis, life expectancy, or treatment response. As a result, many advanced prostate cancer patients are mistreated. New treatments for advanced prostate cancer, available since 2013, have also complicated the physician’s decisions concerning the best therapeutic avenue for each individual patient. PC PrediCare uses a prostate cancer patient's individual clinical information, in combination with sophisticated mathematical modeling technology, to predict his disease progression and response to different treatment regimens. At any stage during the treatment period, the physician can enter the patient's clinical data (PSA profiles, historical biochemistry profiles, Gleason and TNM scoring, response to prior therapies, etc.) into the tool and receive recommendations regarding the most effective treatment path from that point forward.